Blood tests could reveal how ravulizumab helps myasthenia gravis patients

NCT ID NCT07337395

Not yet recruiting Knowledge-focused Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study will analyze blood samples from 24 adults with generalized myasthenia gravis who are being treated with ravulizumab. Researchers will look for changes in thousands of proteins over 26 weeks to find markers that show how well the treatment is working and whether the nerve-muscle connection is healing. The goal is to better understand recovery and improve future care.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ravulizumab
What this could lead to: If successful, this study could identify blood markers that help doctors monitor treatment response and guide therapy for myasthenia gravis.
What could go wrong: This is a small, early-stage observational study (24 people) that looks at proteins in the blood, not a direct test of a new treatment. It may not find clear or useful biomarkers.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates